EAPH (Easton Pharmaceuticals) EBIT per Share : $0.00 (TTM As of Sep. 2021)

View and export this data going back to . Start your Free Trial

What is Easton Pharmaceuticals EBIT per Share?

Easton Pharmaceuticals's EBIT per Share for the three months ended in Sep. 2021 was $0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2021 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Easton Pharmaceuticals's EBIT per Share or its related term are showing as below:

EAPH's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.25
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Easton Pharmaceuticals's EBIT for the three months ended in Sep. 2021 was $-0.08 Mil.

Easton Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Easton Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Easton Pharmaceuticals EBIT per Share Chart

Easton Pharmaceuticals Annual Data

Trend

Dec01

Dec02

Dec03

Dec04

Dec18

Dec19

Dec20

EBIT per Share

Get a 7-Day Free Trial

-167.64

-200.77

Easton Pharmaceuticals Quarterly Data
	Jun02	Sep02	Dec02	Mar03	Jun03	Sep03	Dec03	Mar04	Jun04	Sep04	Dec04	Mar05	Jun05	Sep05	Dec18	Dec19	Dec20	Mar21	Jun21	Sep21
EBIT per Share	Get a 7-Day Free Trial															-	-	-	-	-

Easton Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Easton Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2020 is calculated as

	EBIT per Share		(A: Dec. 2020 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.189	/	1344.932
=	-0.00

Easton Pharmaceuticals's EBIT per Share for the quarter that ended in Sep. 2021 is calculated as

	EBIT per Share		(Q: Sep. 2021 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.084	/	1344.932
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

Easton Pharmaceuticals (OTCPK:EAPH) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Easton Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Easton Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Easton Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Easton Pharmaceuticals Inc (OTCPK:EAPH) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Bloor Street East, Suite 3500, Toronto, ON, CAN, M4W 1A8

Website

http://www.eastonpharmaceuticalsinc.com

Easton Pharmaceuticals Inc is a diversified specialty pharmaceutical company. It owns and develops proprietary transdermal delivery technology and therapeutic over the counter products and drugs to treat cancer and other diseases. The company also owns exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products. It is focused on the development of product Viorra. The firm's products include Nauseasol, Skin Renou HA, Kenestrin gel, and XILIVE, among others.